{"id":"W2969583663","doi":"10.1002/jbm4.10230","title":"Development of Macrocycle Kinase Inhibitors for ALK2 Using Fibrodysplasia Ossificans Progressiva‐Derived Endothelial Cells","year":2019,"lang":"en","type":"article","venue":"JBMR Plus","topic":"Heterotopic Ossification and Related Conditions","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Eshelman Institute for Innovation, University of North Carolina at Chapel Hill; Nederlandse Federatie van Universitair Medische Centra; Ministero dello Sviluppo Economico; Merck Sharp and Dohme; AFM-Téléthon; Novartis Pharma; Canada Foundation for Innovation; AO Foundation; Wellcome Trust; Fundação de Amparo à Pesquisa do Estado de São Paulo; Genome Canada; Ontario Ministry of Economic Development and Innovation; Innovative Medicines Initiative; Cancer Genomics Centre; Diamond Light Source; Instituto de Salud Carlos III; Boehringer Ingelheim; Takeda Pharmaceutical Company; AbbVie; European Federation of Pharmaceutical Industries and Associations; Janssen Pharmaceuticals; Merck KGaA; Pfizer","keywords":"Fibrodysplasia ossificans progressiva; Activin receptor; Ossification; Mesenchymal stem cell; Heterotopic ossification; Cancer research; Cell biology; Bone morphogenetic protein; Signal transduction; Bone morphogenetic protein 2; BMPR2; Myositis ossificans; Medicine; Bioinformatics; Chemistry; Biology; Pathology; Biochemistry; Anatomy; Gene; In vitro","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000208274,0.0004272273,0.0002827346,0.0003078006,0.0001049079,0.0002883037,0.0002773114,0.0003046255,0.0009699193],"category_scores_gemma":[0.0001023838,0.0001154388,0.0002271577,0.0001452925,0.000117531,0.0001676475,0.0001644267,0.0005158116,0.0002877223],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002915248,"about_ca_system_score_gemma":0.0002089921,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007890404,"about_ca_topic_score_gemma":0.001830835,"domain_scores_codex":[0.9999197,0.00001329421,0.000007921756,0.00001500029,0.00002074043,0.00002347168],"domain_scores_gemma":[0.9999455,0.000009184274,0.00001251316,0.000005540534,0.00001061795,0.0000165747],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0002610625,0.0002361947,0.000243919,0.00008421332,0.00002090101,0.0001066978,0.00001777031,0.0007686281,0.9861907,0.0002398177,0.0002919654,0.01153816],"study_design_scores_gemma":[0.0002230195,0.002767184,0.00231447,0.00001582515,0.00005443002,0.0003249368,0.00001874084,0.001882973,0.9829123,0.00004595697,0.009429075,0.00001100403],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9781229,0.01022522,0.005023292,0.0002130673,0.0001062084,0.0002807367,0.0009684783,0.0001334791,0.004926516],"genre_scores_gemma":[0.9862214,0.005102977,0.003984333,0.0001266193,0.00002240922,0.0002031387,0.001410903,0.00001536134,0.002912838],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0009699193,"threshold_uncertainty_score":0.003244698,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02781488964846976,"score_gpt":0.3014132759288842,"score_spread":0.2735983862804145,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}